Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    10986965 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Conditions: Metastatic Melanoma;   Renal Cell Cancer
Intervention: Biological: aldesleukin

Indicates status has not been verified in more than two years